Protein stability
Examine whether a proposed intervention helps maintain the relevant TTR assembly.
Protein biology / Amyloidosis
New possibilities for transthyretin stabilization
Keeping a protein in its working shape can be a powerful treatment strategy. We are exploring how a different approach to transthyretin stabilization could create future options for ATTR amyloidosis.
Early research · Protein stabilization and development strategy
The opportunity
Build on a strategy with a reason to go further
Transthyretin, or TTR, normally forms a four-part protein assembly. Its breakdown and misfolding contribute to ATTR amyloidosis, which can affect the heart and nerves. Existing treatments make this a field with real therapeutic progress. For a new stabilization approach, the opportunity is to offer a meaningful additional benefit in a defined patient and treatment setting.
Our research direction
Connect protein engagement with the benefit that matters
Our direction asks whether a different way of engaging TTR could help preserve its assembled state. The useful development question is what happens after engagement: how the protein behaves, how long an effect lasts and whether that translates into a worthwhile difference. We want to connect molecular design with comparisons that can answer those questions.
Duration and selectivity
Connect engagement over time with functional stabilization and effects on other proteins.
Development relevance
Choose comparisons and outcomes that would establish a reason to advance alongside existing options.
Where we could connect
Bring protein biology and translational priorities together
This direction could fit teams working in amyloidosis, protein biophysics, medicinal chemistry or translational development. A focused collaboration could align an engagement measurement with a functional stability test, then identify what result would justify further work. The starting point is your development question and the expertise each team can contribute.
Explore BioTwin capabilities ↗Questions worth asking
Before we begin
Why pursue stabilization when treatments already exist?
Existing options set the standard a new approach must meet. The question is whether a different engagement strategy could offer a useful profile for a particular setting. That comparison should guide the research from the start.
Would longer engagement mean less frequent dosing?
It is a possibility to investigate, not a property established by engagement alone. Protein turnover, exposure and the duration of functional stabilization would all matter to a dosing strategy.
Is this relevant to every type of amyloidosis?
The initial direction concerns transthyretin-associated, or ATTR, amyloidosis. Other amyloid diseases involve different proteins and would need their own rationale and evaluation.
What could a first collaboration resolve?
We could define a focused comparison linking TTR engagement to stability, including a relevant benchmark and a clear next decision. Detailed research, intellectual property, responsibilities and commercial terms can be discussed for that proposed engagement.
External scientific context
Published background for the research question.
Start a conversation
What would make a new TTR approach worth developing?
Bring your objective, the question you want to resolve and a little non-confidential context. We can discuss the fit and a useful next step.